Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself.

Apollo Health Ventures

Meet us at the Global Healthspan Summit by Hevolution Foundation from November 29th – 30th. Our Co-Founder and Venture Partner Alexandra Sharon Bause will be speaking on two panels this year:

“Follow the Money – Investment for Positive Impact” on Wednesday with Jorge Conde (Andreessen Horowitz), Dr. Andrew Levin (RA Capital Management), Kush Parmar, M.D., Ph.D. (5AM Ventures), and Dr. Christoph Westphal (Longwood Fund). The Panel will be moderated by Dr. Jens Eckstein and Dr. Yury Kukushkin, whom we will share the stage with again the following day.

“Crossing the Valley of Death – Easing the Journey to Market and Long-Term ROI” on Thursday alongside Dr. Matthias Evers (Evotec), Dr. Francisco Leon (Sanofi), Dr. Andrew Levin (RA Capital Management), Matt von Zirkelbach (Eli Lilly and Company), and Dr. Yury Kukushkin (Hevolution Foundation).

Let us know if you want to meet up in Riyadh or email us at info@apollo.vc

#GlobalHealthspanSummit #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Meet us this week in Munich at the Bio Europe from November 6th – 8th. Our Partners Dr. Marianne Mertens and Jan Adams will attend the industry's largest gathering of biopharma professionals in Europe, organized by the EBD Group.

Reach out if you are in town or let us know via email: info@apollo.vc
 
#BIOEurope #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

In Britain, Our Future Health UK is conducting the world’s largest health research study with volunteers to help future generations live in good health for longer. Read the article in The Economist here: https://lnkd.in/dpwU2U-N
 
Milken Institute’s Rajiv Ahuja, JD reflects on the 2022 MEA Summit with one of his discussions centered on the science of longevity that was moderated by our team member Alexandra Sharon Bause. During the discussion, a recurring theme was how aging research is underfunded despite being the top risk factor for chronic diseases. Read all about it in Longevity.Technology: https://lnkd.in/ebkHfEW9
 
An article in Cell Press introduces TEMPO, an innovative approach that combines microvolume liquid-biopsy proteomics, single-cell transcriptomics, and artificial intelligence, has provided insights into the connections between age-related diseases, such as Parkinson’s, and individual cellular aging: https://lnkd.in/e53m_77y
 
Christopher Reyes, PhD and Eyram Adjogatse from our portfolio company Bloom Science, Inc. discuss what the gut-brain axis is and how this intricate connection can revolutionize our understanding and treatment of neurological disorders on Vibe Bio’s Podcast: https://lnkd.in/gm4XUvfH
 
#ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Meet us in London at the Investival Showcase created by LSX - partnering for Life Science eXecutives on November 13th. Our Partner Dr. Marianne Mertens will be on the panel “Unlocking Success: A Strategic Guide For Early Stage Biotechs To Attract Investors” alongside Olga Danilchanka (@MRL Ventures Fund at Merck), Thijs Cohen Tervaert (Inkef), and Daniela Begolo (EQT Life Sciences). 

Reach out to Dr. Marianne Mertens if you are in town or let us know via email: info@apollo.vc
 
#Investival #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Our portfolio company HAYA Therapeutics has made it to HolonIQ’s annual list of the 200 most promising Health Tech startups in Europe from digital health, biotech, medtech, and other areas where entrepreneurs are driving healthcare innovation. 

We are proud to be part of their journey in developing RNA therapies by leveraging the power of the dark genome.

Find out more here: https://lnkd.in/evWGrEpG

#ApolloVC #Healthspan #Lifespan #Longevity #VentureCapital

Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself. They leverage potential by combining traditional funding with venture building, acquiring founder shares at nominal value. They also identify and invest in best-in-class companies at an early stage.

VC:APOLLO

Apollo Health Ventures

Filings Not Available